Prothena Biosciences is a pioneering company with over three decades of expertise in the biology of misfolded proteins, focusing on transformative medicines for neurodegenerative disorders. Committed to scientific excellence, Prothena's diverse pipeline targets diseases linked to protein dysregulation, including Parkinson’s Disease, Alzheimer’s Disease, and ATTR Amyloidosis. Through rigorous research and clinical trials, Prothena aims to develop novel therapeutics that provide significant clinical benefits to patients affected by these debilitating conditions.

The company's pipeline features promising investigational products such as prasinezumab, coramitug (PRX004), and BMS-986446 (PRX005). By leveraging their deep understanding of neurological dysfunction, Prothena strives to create impactful therapies that can improve the lives of millions. Their commitment to innovation is evident in their collaborative approach with leading researchers and clinicians in the field. As Prothena continues to push the boundaries of neuroscience, they are dedicated to making a real difference for patients and their families worldwide.